A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, ...

(Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). “While AK006 was well tolerated, we are disappointed ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

Allakos (NASDAQ:ALLK) has dropped ~75% in premarket trading Monday after posting disappointing phase 1 results on AK006 for chronic spontaneous urticaria and deciding to end development. Due to ...

California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing ...

Allakos (ALLK) announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria. In the CSU cohort, 34 adult ...

and painful hives. Credit: Doucefleur via Getty Images. Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...